Ardelyx Inc (41X.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 01:25PM CEST. Market open.
| Previous close | 6.16 |
| Open | 6.68 |
| Bid | 7.34 x 0 |
| Ask | 7.49 x 0 |
| Day's range | 6.68 - 8.12 |
| 52-week range | 2.97 - 9.46 |
| Volume | |
| Avg. volume | 448 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksArdelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireArdelyx Reports First Quarter 2024 Financial Results and Provides Business Update
Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-cl
© 2024 Yahoo. All rights reserved.